Bonus Biogroup (TASE: BONS) is an advanced clinical-stage biotechnology company developing 'next-generation' therapies for a variety of indications in the regenerative medicine field. As pioneers in the industry, we leverage our extensive knowledge and expertise to establish a unique technological platform, which underpins the development of our leading products, BonoFill™ and MesenCure™.
Bonus Biogroup strives to Empower millions of patients to live healthier and longer lives through scientific leadership and excellence, technological innovation, and a patient-centric approach.
We aim to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products to address severe conditions representing multi-billion-dollar markets with limited treatment options.